查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1999192

細胞和基因治療製造服務市場：2026-2032年全球市場預測（按服務類型、技術類型、治療領域、應用和最終用戶分類）

Cell & Gene Therapy Manufacturing Services Market by Service Type, Technology Type, Therapeutic Area, Application, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，細胞和基因治療製造服務市場價值將達到 230.6 億美元，到 2026 年將成長至 266.1 億美元，到 2032 年將達到 669.2 億美元，複合年成長率為 16.43%。

主要市場統計數據
基準年 2025 230.6億美元
預計年份：2026年 266.1億美元
預測年份：2032年 669.2億美元
複合年成長率 (%) 16.43%

權威的介紹說明了為什麼細胞和基因治療製造服務對於臨床成功和商業化策略至關重要。

細胞和基因治療生產服務產業已從零散的先導計畫發展成為先進療法開發中至關重要的策略要素。如今，卓越的生產能力不僅決定臨床應用的速度，也決定複雜生技藥品商業化的可行性。本執行摘要概述了正在重塑企業制定生產策略和選擇外部合作夥伴方式的營運、技術、監管和商業性趨勢。

技術進步、營運數位化和監管期望共同作用，迫使整個細胞和基因治療製造服務進行策略重組。

該產業正經歷一場變革性的變革，這場變革從根本上改變了治療方法的研發和生產方式。基因編輯技術的進步、病毒和非病毒載體的日益普及以及先進分析工具的出現，提高了人們對療法可重複性和療效的技術要求。同時，基於平台的製程開發和模組化設施設計正在興起，這不僅能加快生產規模，也能確保產品品質和符合監管要求。

了解 2025 年美國關稅措施對全球供應鏈和製造業韌性的多層次營運和策略影響。

2025年推出的最新關稅措施進一步加劇了本已錯綜複雜的細胞和基因治療生產全球供應鏈的複雜性。進口關稅及相關貿易措施提高了許多進口原料、特殊試劑和生產設備的相對成本和前置作業時間。因此，各機構正在重新審視其供應商組合和籌資策略，以減輕跨境價格波動的影響。

詳細的細分分析揭示了服務類型、技術平台、治療領域、應用和最終用戶需求如何塑造提供者的定位。

細分市場分析揭示了不同服務類型、技術平台、治療適應症、應用場景和最終用戶類別所面臨的優先挑戰各不相同。每種服務類型——分析和品管服務、細胞庫服務、諮詢服務、灌裝和包裝服務、GMP生產服務、製程開發服務、法規支援服務、供應鏈物流服務、技術轉移服務和載體生產服務——都面臨獨特的能力和產能要求。能夠提供將載體生產與強大的分析和法規支援相結合的整合服務方案的供應商，對尋求透過單一供應商降低風險的開發商更具吸引力。另一方面，專注於有限服務範圍的高度專業化供應商，可以透過提供卓越的技術深度和客製化解決方案來佔據市場領先地位。

區域比較分析，闡述美洲、歐洲、中東和非洲以及亞太地區如何影響戰略製造和夥伴關係決策。

區域趨勢顯著影響企業在生產能力投資地點、合作夥伴選擇以及專業能力配置方面的決策。在美洲，由契約製造、大學衍生企業和創業投資支持的研發公司組成的密集生態系統，為轉化研究提供了快速通道，同時監管機構也為先進治療方法提供了日益成熟的指導框架。鑑於大規模的患者群體和接近性資本市場的地理優勢，這種環境有利於垂直整合策略和載體生產能力的投資。

企業策略行動和競爭動態決定了哪個供應商贏得訂單以及如何建立夥伴關係。

企業行為揭示了這樣一個市場現實：策略差異化源自於廣泛的能力、技術專長和夥伴關係模式。領先的服務供應商透過整合載體生產、製程開發和分析平台的投資，提供從早期開發到商業化的一體化流程。這些能力吸引了尋求可預測進度的贊助商，因為它們減少了技術交接環節，並降低了專案風險。同時，專注於高度複雜細分領域（例如AAV生產、非病毒遞送平台或高級分析）的專業公司，憑藉其可重複的技術性能和深厚的監管專業知識，贏得了高價值合約。

為產業領導者提供實際有效的建議，以加強供應鏈、加速技術轉移並確保製造業的未來發展。

領導者應優先採取一系列切實可行的措施，以降低風險、加速研發進度並保障利潤率。首先，應實現關鍵試劑和設備的來源多元化，核實二級供應商的合格，並建立長期合約保障機制，以降低關稅和供應鏈中斷的影響。同時，應投資建立強大的分析能力和標準化檢測方法，以縮短技術轉移過程中的資格確認週期，並加快監管申報流程。

一種透明的混合研究途徑，結合了與專家的初步訪談、能力映射和情境檢驗，以支持策略洞察。

支持這些見解的研究採用了一種混合方法，結合了專家訪談、技術評估和文件分析。主要資訊來源包括對申辦方和提供方機構生產部門的高階主管、品質經理和法規專家進行的結構化訪談，從而深入觀點營運限制和策略重點。這些定性見解與監管指南、同行評審文獻以及公開資訊的技術審查進行了交叉比對，以檢驗有關技術趨勢和能力的論點。

簡明扼要地總結了為何生產能力、監管合規性和供應鏈韌性是決定先進治療方法開發成功與否的關鍵因素。

細胞和基因治療生產服務領域正處於轉折點，技術進步、不斷變化的監管環境以及地緣政治因素共同塑造戰略選擇。建構模組化、數據主導流程並建立多元化供應商網路的供應商和申辦方，更有可能克服關稅阻力和區域營運的複雜性。儘早與監管機構溝通並建立可驗證的品管體系，仍然是成功進行技術轉移和商業化的必要前提。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：細胞與基因治療製造服務市場：依服務類型分類

  • 分析和品管服務
  • 手機銀行服務
  • 諮詢服務
  • 灌裝和精加工服務
  • GMP生產服務
  • 流程開發服務
  • 監理合規服務
  • 供應鏈物流服務
  • 技術轉移服務
  • 向量製作服務

第9章：細胞與基因治療製造服務市場：依技術類型分類

  • 基因編輯
    • CRISPR/Cas9
    • 轉錄活化因子樣效應核酸酶
    • 鋅指核酸酶
  • 向量
    • 非病毒載體
      • 陽離子脂質
      • 基於幾丁聚醣的載體
      • 樹狀聚合物
      • 無機奈米粒子
      • 脂質奈米顆粒
      • 裸露的DNA/RNA
      • 基於胜肽的載體
      • 聚合物載體
    • 病毒載體
      • 腺結合病毒（AAV）載體
      • 腺病毒載體
      • 單純皰疹病毒（HSV）載體
      • 逆轉錄病毒載體

第10章 細胞與基因治療製造服務市場：依治療領域分類

  • 心血管疾病
    • 冠狀動脈疾病
    • 心臟衰竭
  • 感染疾病
    • B型肝炎
    • HIV
  • 單基因疾病
    • 囊腫纖維化
    • 血友病
    • 鐮狀細胞貧血症
  • 腫瘤學
    • 骨髓惡性腫瘤
    • 固體癌

第11章：細胞與基因治療製造服務市場：依應用領域分類

  • 臨床生產
  • 商業製造

第12章 細胞與基因治療製造服務市場：依最終用戶分類

  • 合約研究機構
  • 醫院和診所
  • 製藥和生物技術公司
  • 研究機構和學術機構

第13章：細胞與基因治療製造服務市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：細胞與基因治療製造服務市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 細胞與基因療法製造服務市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國細胞與基因治療製造服務市場

第17章：中國細胞與基因治療製造服務市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Advanced BioScience Laboratories, Inc. （Institut Merieux）
  • AGC Biologics
  • AmplifyBio
  • Bio-Techne Corporation
  • CH Boehringer Sohn AG & Co. KG
  • Catalent, Inc.
  • Cell Therapies Pty Ltd.
  • Cell-Easy
  • Charles River Laboratories International, Inc.
  • Danaher Corporation
  • eXmoor Pharma Concepts Limited
  • FUJIFILM Diosynth BIoTechnologies
  • Genezen Laboratories, Inc.
  • Laboratory Corporation of America Holdings
  • Lonza Group AG
  • Merck KGaA
  • Miltenyi BIoTec BV & Co. KG
  • Minaris Regenerative Medicine GmbH by Resonac Corporation
  • Nikon Corporation
  • Novartis AG
  • Oxford Biomedica PLC
  • ProPharma Group Holdings, LLC
  • Recipharm AB
  • Samsung Biologics Co., Ltd.
  • SGS SA
  • STEMCELL Technologies Inc.
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • uBriGene Biosciences Inc.
  • WuXi AppTec Co., Ltd.
Product Code: MRR-BB6269D1414B

The Cell & Gene Therapy Manufacturing Services Market was valued at USD 23.06 billion in 2025 and is projected to grow to USD 26.61 billion in 2026, with a CAGR of 16.43%, reaching USD 66.92 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 23.06 billion
Estimated Year [2026] USD 26.61 billion
Forecast Year [2032] USD 66.92 billion
CAGR (%) 16.43%

An authoritative introduction framing why manufacturing services for cell and gene therapies are now pivotal to clinical success and commercialization strategies

The cell and gene therapy manufacturing services landscape has matured from fragmented pilot projects to a strategically critical component of advanced therapeutics development. Manufacturing excellence now determines not only the speed of clinical translation but also the viability of commercialization for complex biologics. This executive summary synthesizes operational, technological, regulatory, and commercial dynamics that are reshaping how organizations design manufacturing strategies and select external partners.

Across the value chain, precision in analytical methods, reliability in supply chains, and robustness in process development have become decisive competitive differentiators. Manufacturers and service providers must simultaneously manage biologic complexity, regulatory stringency, and an increasingly globalized supplier base. Consequently, senior leaders are prioritizing investments in platform technologies, quality systems, and integrated services that reduce technical risk while accelerating time to clinic.

The following sections examine structural shifts, the implications of recent trade policy interventions, segmentation-specific dynamics, regional contrasts, corporate strategic behaviors, and pragmatic recommendations for industry leaders. Each element is framed to support clear decision-making pathways for organizations evaluating manufacturing partnerships, capacity investments, or capability development initiatives.

How converging technical advances, operational digitization, and regulatory expectations are forcing strategic reinvention across cell and gene therapy manufacturing services

The industry is undergoing transformative shifts that are altering the fundamentals of how therapies are developed and manufactured. Advances in gene editing, expanding use cases for viral and non-viral vectors, and refined analytical tools are raising technical expectations for reproducibility and potency. In tandem, a move toward platform-based process development and modular facility designs is enabling faster scale-up while preserving product quality and regulatory compliance.

Operationally, digitization and automation are reducing variability and labor dependence in critical workflows. Machine learning and process analytics are increasingly applied to in-process controls and batch release decisions, improving lot consistency and accelerating release timelines. At the same time, decentralized and hybrid manufacturing models are gaining traction, driven by the need for geographic proximity to patients and by logistical imperatives for temperature-sensitive material handling.

Regulatory engagement has also evolved; regulators are placing greater emphasis on lifecycle quality management, comparability, and long-term safety monitoring. This has prompted closer collaboration between developers, contract manufacturers, and regulators earlier in development. Finally, strategic capital is flowing into specialized contract development and manufacturing organizations that can offer integrated services across vector production, process development, and GMP manufacturing, underscoring a market-wide shift toward end-to-end propositions that de-risk development programs.

Understanding the layered operational and strategic consequences of the 2025 United States tariff measures on global supply chains and manufacturing resilience

Recent tariff actions introduced in 2025 have created a complex overlay on an already intricate global supply chain for cell and gene therapy manufacturing. Import duties and related trade measures have increased the relative cost and lead time of many imported raw materials, specialized reagents, and manufacturing equipment. As a result, organizations are reassessing supplier portfolios and procurement strategies to mitigate exposure to cross-border pricing volatility.

In response, many developers and service providers have accelerated localization of critical inputs and invested in qualifying domestic suppliers to secure continuity of supply. These efforts often require parallel investments in quality assurance and regulatory alignment to ensure substitutes meet stringent GMP expectations. Consequently, procurement teams are devoting more resources to supplier qualification, audit readiness, and long-term contracting mechanisms that lock in quality and delivery terms.

Contract manufacturers and technology vendors are adjusting commercial models to absorb some tariff-related friction through alternative sourcing, forward purchasing, and contractual pricing clauses. Moreover, trade measures have intensified the strategic rationale for regional manufacturing footprints, where proximity reduces tariff exposure, shortens distribution pathways, and enhances compliance with local regulatory frameworks. Taken together, the cumulative impact of tariffs is not only financial but also structural, prompting organizations to rethink how manufacturing networks should be organized for resilience and regulatory congruence.

Deep segmentation insights that reveal how distinct service types, technology platforms, therapeutic focuses, applications, and end-user needs shape provider positioning

Segmentation analysis reveals differentiated imperatives across service types, technology platforms, therapeutic indications, application contexts, and end-user categories. Service types such as Analytical & Quality Control Services, Cell Banking Services, Consulting Services, Fill & Finish Services, GMP Manufacturing Services, Process Development Services, Regulatory Support Services, Supply Chain & Logistics Services, Technology Transfer Services, and Vector Production Services each face unique capability and capacity demands. Providers offering integrated suites that combine vector production with robust analytics and regulatory support achieve greater appeal to developers seeking single-vendor risk reduction. Conversely, highly specialized providers that concentrate on a narrow set of services can secure premium positioning by delivering superior technical depth and bespoke solutions.

Technology type segmentation differentiates organizations working in Gene Editing and Vectors. Within Gene Editing, approaches such as CRISPR/Cas9, Transcription Activator-Like Effector Nucleases, and Zinc Finger Nucleases require distinct process development pathways and regulatory dossiers. Vector technologies split into Non-Viral and Viral Vectors; Non-Viral Vectors encompass cationic lipids, chitosan-based vectors, dendrimers, inorganic nanoparticles, liposomes, naked DNA/RNA, peptide-based vectors, and polymeric vectors, each with divergent formulation and delivery considerations. Viral Vectors include adeno-associated virus vectors, adenovirus vectors, herpes simplex virus vectors, and retrovirus vectors, and these necessitate specialized containment, production platforms, and potency assays. Firms that can demonstrate cross-platform expertise or rapid transferability between these technology types are better positioned to capture emerging program demand.

Therapeutic area segmentation distinguishes development pathways across cardiovascular diseases, infectious diseases, monogenic disorders, and oncology. Within cardiovascular diseases, programs focused on coronary artery disease and heart failure require distinct safety and delivery strategies compared with infectious disease programs targeting hepatitis B or HIV. Monogenic disorder efforts such as cystic fibrosis, hemophilia, and sickle cell anemia emphasize curative intent and long-term follow-up, imposing rigorous controls on vector biodistribution and persistence. Oncology programs, split between hematological malignancies and solid tumors, demand divergent manufacturing scales and release criteria due to differing dosing paradigms and cell types.

Application-based segmentation differentiates clinical manufacturing from commercial manufacturing. Clinical manufacturing emphasizes flexibility, rapid changeover, and small-batch reproducibility, while commercial manufacturing demands robust scale, cost efficiencies, and validated high-throughput analytics. End-user segmentation highlights the varied buying behaviors and capability expectations of contract research organizations, hospitals & clinics, pharmaceutical & biotech companies, and research institutes & academic institutions. CROs prioritize rapid turnaround and regulatory alignment, hospitals and clinics seek localized solutions for patient-centric delivery, pharmaceutical and biotech companies emphasize integrated development-to-commercial pathways, and research institutes focus on platform access and technology transfer support. Understanding these intersecting segmentation layers enables providers and sponsors to tailor propositions that align technical strengths with buyer priorities and therapeutic requirements.

Comparative regional intelligence explaining how the Americas, Europe Middle East & Africa, and Asia-Pacific each shape strategic manufacturing and partnership decisions

Regional dynamics materially influence where organizations choose to invest in capacity, partner with contractors, and locate specialized capabilities. In the Americas, a dense ecosystem of contract manufacturers, academic spinouts, and venture-backed developers supports rapid translational pathways, while regulatory agencies are offering increasingly mature guidance frameworks for advanced therapies. This environment encourages vertically integrated strategies and investments in vector production capacity, given the proximity to large patient populations and capital markets.

Europe, the Middle East & Africa present a heterogeneous landscape, with centers of excellence clustered in countries that combine favorable regulatory clarity with advanced biomanufacturing infrastructure. Cross-border collaborations within Europe facilitate access to skilled labor and analytic expertise, yet fragmented reimbursement and localized regulatory nuances require tailored market entry strategies. In parts of the Middle East and Africa, strategic partnerships and knowledge transfer initiatives are emerging, often driven by government-led capacity-building programs.

Asia-Pacific stands out for rapid expansion of manufacturing capacity, significant public and private investment in biotech ecosystems, and a growing cadre of specialized manufacturing service providers. Regulatory pathways in several jurisdictions are evolving to accommodate advanced therapies, and regional supply chain advantages-particularly in reagents and equipment manufacturing-are prompting multinational developers to consider Asia-Pacific-based production as part of global strategies. Each region's regulatory posture, talent availability, and supply chain topology should inform decisions about where to site facilities, which services to insource, and how to structure commercial partnerships for long-term resilience.

Strategic company behaviors and competitive dynamics that determine which providers are winning mandates and how partnerships are being structured

Corporate behaviors reveal a market in which strategic differentiation emerges from capability breadth, technological specialization, and partnership models. Leading service providers are combining investments in vector production, process development, and analytical platforms to offer integrated pathways from early development through commercialization. These capabilities reduce technical handoffs and lower program risk, attracting sponsors seeking predictable timelines. At the same time, specialized firms that focus on high-complexity niches-such as AAV manufacturing, non-viral delivery platforms, or advanced analytics-are capturing premium mandates by demonstrating reproducible technical performance and deep regulatory know-how.

Strategic alliances and M&A activity are common mechanisms for acquiring missing capabilities rapidly, particularly when organizations aim to move from service provision to platform ownership. Outsourcing models continue to diversify; some pharmaceutical and biotech companies pursue co-investment in dedicated facilities to secure capacity, while others prefer flexible, fee-for-service engagements. Quality systems, regulatory track records, and demonstrated technology transfer experience are decisive contracting criteria. Additionally, firms that adopt digital quality management systems, robust batch record traceability, and advanced environmental monitoring differentiate themselves through lower deviation rates and faster regulatory inspections.

The competitive landscape also values transparent risk-sharing agreements, milestone-based pricing, and hybrid commercial structures that align incentives between sponsors and manufacturers. Finally, a growing subset of companies is investing in sustainable manufacturing practices and circular supply chain initiatives, which signal long-term operational discipline and can influence procurement decisions among environmentally conscious sponsors.

Practical high-impact recommendations for industry leaders to fortify supply chains, accelerate technology transfer, and future-proof manufacturing operations

Leaders should prioritize a set of actionable measures that reduce risk, accelerate development timelines, and protect margins. First, diversify sourcing for critical reagents and equipment while qualifying secondary suppliers and establishing long-term contractual safeguards to mitigate tariff and supply chain disruptions. Parallel to this, invest in robust analytical capability and standardized assays to shorten qualification timelines during technology transfer and to support faster regulatory submissions.

Second, adopt modular and platform-focused process architectures that enable seamless scale transitions from clinical to commercial contexts. This includes standardizing unit operations, harmonizing documentation, and embedding digital process controls to lower variability. Third, pursue strategic partnerships that combine technical depth with commercial reach; co-locating vector production with downstream fill-and-finish or analytics can materially reduce handoff risks and improve overall program timelines.

Fourth, engage proactively with regulators earlier in development to align on comparability strategies, potency assays, and long-term safety monitoring. Fifth, enhance workforce competency through targeted upskilling programs focused on GMP best practices, advanced analytics, and equipment automation. Sixth, consider regional footprint decisions through the lens of tariff exposure, talent availability, and proximity to clinical sites. Finally, incorporate sustainability metrics into facility planning and supplier selection to reduce long-term operational risk and to meet emerging stakeholder expectations.

A transparent hybrid research approach blending primary expert interviews, capability mapping, and scenario validation to underpin strategic insights

The research underpinning these insights relied on a hybrid methodology that combined expert interviews, technology assessments, and documentary analysis. Primary inputs included structured interviews with senior manufacturing leaders, quality heads, and regulatory experts across sponsor and provider organizations, which provided granular perspectives on operational constraints and strategic priorities. These qualitative insights were triangulated with technical reviews of regulatory guidance, peer-reviewed literature, and public disclosures to validate technology trends and capability claims.

A detailed capability-mapping exercise assessed service providers across vector production, process development, GMP manufacturing, analytics, and regulatory support. Technology readiness and transferability were evaluated through criteria such as platform maturity, historical comparability studies, and demonstrated commercial-scale runs. Supply chain resilience assessments considered supplier concentration, geographic exposure, and lead-time sensitivities.

Data validation included cross-referencing interview findings with third-party technical reports and observed regulatory outcomes. Scenario-based analysis explored alternative configurations for manufacturing networks and supplier strategies under varying trade and capacity conditions. The methodology emphasized transparency and reproducibility: documentation of interview protocols, inclusion criteria for capability assessments, and the rationale for scenario parameters are available to buyers as part of the research package.

A concise concluding perspective on why manufacturing capability, regulatory alignment, and supply chain resilience will determine success in advanced therapy development

The cell and gene therapy manufacturing services sector stands at an inflection point where technical progress, regulatory evolution, and geopolitical influences collectively shape strategic choices. Providers and sponsors that build modular, analytics-driven processes and secure diversified supplier networks will be better equipped to navigate tariff-driven headwinds and regional operational complexities. Early regulatory engagement and demonstrable quality systems remain non-negotiable prerequisites for successful technology transfer and commercialization.

Organizations must balance the competing imperatives of scale, flexibility, and risk reduction. Those that opt for integrated platform strategies or targeted partnerships can shorten timelines and lower program attrition, while specialists that concentrate on niche capabilities will continue to be essential for addressing high-complexity technical challenges. Ultimately, deliberate investments in process standardization, workforce capability, and regional resilience will determine competitive positioning in a market where manufacturing excellence increasingly equals therapeutic success.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cell & Gene Therapy Manufacturing Services Market, by Service Type

  • 8.1. Analytical & Quality Control Services
  • 8.2. Cell Banking Services
  • 8.3. Consulting Services
  • 8.4. Fill & Finish Services
  • 8.5. GMP Manufacturing Services
  • 8.6. Process Development Services
  • 8.7. Regulatory Support Services
  • 8.8. Supply Chain & Logistics Services
  • 8.9. Technology Transfer Services
  • 8.10. Vector Production Services

9. Cell & Gene Therapy Manufacturing Services Market, by Technology Type

  • 9.1. Gene Editing
    • 9.1.1. CRISPR/Cas9
    • 9.1.2. Transcription Activator-Like Effector Nucleases
    • 9.1.3. Zinc Finger Nucleases
  • 9.2. Vectors
    • 9.2.1. Non-Viral Vectors
      • 9.2.1.1. Cationic Lipids
      • 9.2.1.2. Chitosan-Based Vectors
      • 9.2.1.3. Dendrimers
      • 9.2.1.4. Inorganic Nanoparticles
      • 9.2.1.5. Liposomes
      • 9.2.1.6. Naked DNA/RNA
      • 9.2.1.7. Peptide-Based Vectors
      • 9.2.1.8. Polymeric Vectors
    • 9.2.2. Viral Vectors
      • 9.2.2.1. Adeno-Associated Virus (AAV) Vectors
      • 9.2.2.2. Adenovirus Vectors
      • 9.2.2.3. Herpes Simplex Virus (HSV) Vectors
      • 9.2.2.4. Retrovirus Vectors

10. Cell & Gene Therapy Manufacturing Services Market, by Therapeutic Area

  • 10.1. Cardiovascular Diseases
    • 10.1.1. Coronary Artery Disease
    • 10.1.2. Heart Failure
  • 10.2. Infectious Diseases
    • 10.2.1. Hepatitis B
    • 10.2.2. HIV
  • 10.3. Monogenic Disorders
    • 10.3.1. Cystic Fibrosis
    • 10.3.2. Hemophilia
    • 10.3.3. Sickle Cell Anemia
  • 10.4. Oncology
    • 10.4.1. Hematological Malignancies
    • 10.4.2. Solid Tumors

11. Cell & Gene Therapy Manufacturing Services Market, by Application

  • 11.1. Clinical Manufacturing
  • 11.2. Commercial Manufacturing

12. Cell & Gene Therapy Manufacturing Services Market, by End-User

  • 12.1. Contract Research Organizations
  • 12.2. Hospitals & Clinics
  • 12.3. Pharmaceutical & Biotech Companies
  • 12.4. Research Institutes & Academic Institutions

13. Cell & Gene Therapy Manufacturing Services Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cell & Gene Therapy Manufacturing Services Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cell & Gene Therapy Manufacturing Services Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Cell & Gene Therapy Manufacturing Services Market

17. China Cell & Gene Therapy Manufacturing Services Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Advanced BioScience Laboratories, Inc. by Institut Merieux
  • 18.6. AGC Biologics
  • 18.7. AmplifyBio
  • 18.8. Bio-Techne Corporation
  • 18.9. C.H. Boehringer Sohn AG & Co. KG
  • 18.10. Catalent, Inc.
  • 18.11. Cell Therapies Pty Ltd.
  • 18.12. Cell-Easy
  • 18.13. Charles River Laboratories International, Inc.
  • 18.14. Danaher Corporation
  • 18.15. eXmoor Pharma Concepts Limited
  • 18.16. FUJIFILM Diosynth Biotechnologies
  • 18.17. Genezen Laboratories, Inc.
  • 18.18. Laboratory Corporation of America Holdings
  • 18.19. Lonza Group AG
  • 18.20. Merck KGaA
  • 18.21. Miltenyi Biotec B.V. & Co. KG
  • 18.22. Minaris Regenerative Medicine GmbH by Resonac Corporation
  • 18.23. Nikon Corporation
  • 18.24. Novartis AG
  • 18.25. Oxford Biomedica PLC
  • 18.26. ProPharma Group Holdings, LLC
  • 18.27. Recipharm AB
  • 18.28. Samsung Biologics Co., Ltd.
  • 18.29. SGS S.A.
  • 18.30. STEMCELL Technologies Inc.
  • 18.31. Takara Bio Inc.
  • 18.32. Thermo Fisher Scientific Inc.
  • 18.33. uBriGene Biosciences Inc.
  • 18.34. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ANALYTICAL & QUALITY CONTROL SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ANALYTICAL & QUALITY CONTROL SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ANALYTICAL & QUALITY CONTROL SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL BANKING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL BANKING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL BANKING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CONSULTING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CONSULTING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CONSULTING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY FILL & FINISH SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY FILL & FINISH SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY FILL & FINISH SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GMP MANUFACTURING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GMP MANUFACTURING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GMP MANUFACTURING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGULATORY SUPPORT SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGULATORY SUPPORT SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGULATORY SUPPORT SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SUPPLY CHAIN & LOGISTICS SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SUPPLY CHAIN & LOGISTICS SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SUPPLY CHAIN & LOGISTICS SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TRANSFER SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TRANSFER SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TRANSFER SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTOR PRODUCTION SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTOR PRODUCTION SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTOR PRODUCTION SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CRISPR/CAS9, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CRISPR/CAS9, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CRISPR/CAS9, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ZINC FINGER NUCLEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ZINC FINGER NUCLEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ZINC FINGER NUCLEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CATIONIC LIPIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CATIONIC LIPIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CATIONIC LIPIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CHITOSAN-BASED VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CHITOSAN-BASED VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CHITOSAN-BASED VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY DENDRIMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY DENDRIMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY DENDRIMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INORGANIC NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INORGANIC NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INORGANIC NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY LIPOSOMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY LIPOSOMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY LIPOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NAKED DNA/RNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NAKED DNA/RNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NAKED DNA/RNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PEPTIDE-BASED VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PEPTIDE-BASED VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PEPTIDE-BASED VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY POLYMERIC VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY POLYMERIC VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY POLYMERIC VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV) VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV) VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV) VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENOVIRUS VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENOVIRUS VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENOVIRUS VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY RETROVIRUS VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY RETROVIRUS VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY RETROVIRUS VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEART FAILURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEPATITIS B, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HIV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HIV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HIV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CYSTIC FIBROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CYSTIC FIBROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEMOPHILIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEMOPHILIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEMOPHILIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SICKLE CELL ANEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SICKLE CELL ANEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SICKLE CELL ANEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CLINICAL MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CLINICAL MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CLINICAL MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY RESEARCH INSTITUTES & ACADEMIC INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY RESEARCH INSTITUTES & ACADEMIC INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY RESEARCH INSTITUTES & ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 238. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 240. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 253. AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 254. AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 255. AFRICA CELL & GENE THERAPY MANUFACT